Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Asad Haider, head of the healthcare business unit within Goldman Sachs Research, now forecasts the market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, to ...

Detailed price information for Bank of Montreal (BMO-N) from The Globe and Mail including charting and trades.

Novartis launched a tender offer for Regulus Therapeutics. Biogen and City Therapeutics announced a partnership to develop a drug for an undisclosed central nervous system disease. Eli Lilly bought ...

Eli Lilly is making waves by acquiring SiteOne Therapeutics for up to $1 billion, eyeing a non-opioid chronic pain treatment.

Eli Lilly and Company and SiteOne Therapeutics, Inc., a private biotechnology company developing small molecule inhibitors of ...

Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which ...

In this week’s edition of InnovationRx, we look at how Hinge Health’s successful IPO may be a trendsetter, Indian billionaire ...

An intravenous immunoglobulin treatment made from human plasma (Panzyga) led to a numerical, but not significantly greater, ...

Pharmaceutical company Eli Lilly has announced plans to acquire private biotech company SiteOne in a deal worth up to $1 ...